Press Releases & Media Statements

Reset all filters

Collaboration with Mary Tyler Moore Vision Initiative

Faces of two women

Developing treatments for people with mental health conditions

laboratory equipment

Boehringer Ingelheim collaborates with Circle Pharma

Scientist at work

Boehringer receives U.S. FDA Breakthrough Therapy designation for MASH

Lab Research

Topline results from Boehringer's Phase III IPF Study

A female physician reviews information on a tablet

Positive results reported in HER2 mutated lung cancer

picture of a researcher in a white lab coat and lab goggles

Boehringer Ingelheim to unveil oncology research at WCLC

picture of a woman in a white lab coat and lab goggles holding a pipette tool

First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones

Lab workers

New affordability initiative with GoodRx for our biosimilar

People on computer

New effort to help improve C-R-M health outcomes

Results from Phase II MASH trial presented at EASL 2024

Liver graphic

Boehringer inhalers now available at $35 a month for eligible patients

Woman with brown hair standing outside in front of blue sky

New agreement with Quallent expands biosimilar access

Pharmacist talking with patient

Improving Access to Clinical Trials

Scientists

FDA Approves Additional Formulation of Our Biosimilar

Doctor speaking with patient.

Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline.

Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline.

Results announced from EMPACT-MI phase III trial

Scientists working together

New FDA approval for the treatment of GPP

photo of male researcher working in a lab

Update on sNDA for fibrosing ILD in children and adolescents

Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month

Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month

Top-line Phase II Data for treatment of MASH

Liver Illustration

National Psoriasis Foundation Releases Consensus Statement on Management of Generalized Pustular Psoriasis (GPP)

photo of female physician in conversation with colleagues

Investigational Compound Granted FDA Orphan Drug Designation

photo of researcher

Promising Phase II Results in Chronic Kidney Disease

Kidney Illustration

AI-Driven Model Validated to Predict Risk of CKD Progression

Kidney Illustration

Hip-Hop Classic “It Takes Two” Takes on New Meaning in Remix to Elevate Importance of Testing for Kidney Disease

doctor, patient and Rob Base

Life forward - Boehringer Ingelheim unveils its evolved company brand

two childrens

Boehringer Ingelheim wins 2023 Prix Galien USA

Recipients of the 2023 Prix Galien USA

Low-WAC interchangeable biosimilar is now available

Physician talking with patient

FDA Approved Treatment Option for Adults with CKD

Patient talking to doctor

Statement by Boehringer Ingelheim on selection of Jardiance® (empagliflozin) by the Centers for Medicare and Medicaid Services (CMS) Drug Price Negotiation Program

First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas

For download: © 2020, Peter Ginter

FDA accepts OFEV sNDA for 6–17-year-olds with fibrosing ILD

animation of child sitting on couch and smiling with caregiver

Interchangeable Biosimilar Now on Express Scripts® Formulary

Physician talking with patient

Boehringer Ingelheim presents Effisayil™ 2 trial results

A graphic showing a person's hand touching a screen with imagery and data

Interchangeable biosimilar now available in the U.S.

Physician talking with patient

Boehringer Ingelheim and FIT Unveil Fifth Piece for The Unwearable Collection

Trapped by Uncertainty

Optum Rx Places Interchangeable Biosimilar on its Commercial Formulary

physician talking with patient

FDA approves treatment option for T2D in children 10 and older

DINAMO

FDA approves autoinjector pen for Interchangeable biosimilar

Physician talking with patient

IL-11 inhibitor antibody clinical development launched

Fibroblasts

U.S. FDA Grants Breakthrough Therapy designation

HCP looking at tablet

J-Code Issued for SPEVIGO

Spevigo-J-code

Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth

Press Release

FDA accepts Jardiance sNDA for T2D in children 10 and older

Preteen boy smiling

Intensive education about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines

Healthcare provider and patient at appointment

Boehringer Ingelheim announces new partnership to support awareness of GPP

The Unwearable Collection Designs

US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease.

Senior couple laughing on couch

New cancer therapeutics collaboration with 3T Bio

monecules

Boehringer Ingelheim and Click Therapeutics Expand their Existing Collaboration to Develop Prescription Digital Therapeutics for Schizophrenia

New Digital Tx collab with Click

Full data announced in DINAMO trial in young people with T2D

Boehringer Ingelheim Welcomes New 2023 GOLD Report Positioning LAMA/LABA as the Preferred Treatment for the Majority of Patients with COPD

Hands on a tablet

Full data announced in phase III EMPA-KIDNEY trial

First patient enrolled in FIBRONEER™-IPF Phase III trial

First patient enrolled in FIBRONEER™-IPF Phase III trial

Boehringer Ingelheim announces expanded access program

New Expanded Access Program for children and adolescents with fibrosing ILD

Boehringer Ingelheim announces InPedILD PhaseIII trial results

New Phase III data in children presented at ERS 2022

Boehringer Ingelheim introduces Tune In To Lung Health

Photo of Tune In To Lung Health spokesperson Bernie Williams seated at piano, playing guitar and smiling at three women who are affected by interstitial lung disease

FDA approves the first treatment option for generalized pustular psoriasis flares in adults

Lab_tech_conducts_testing

First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline

Doctor touching a virtual screen with images of VR technology, medication, biotech, stethoscopes, global networks, a cell phone, a laptop, and a patient. There are graphic symbols depicting medicine, health, pharmaceuticals, innovation, research, cardiology, pulmonology, and the words “medical” and “24/7”.

Real-world data announced for adults with type 2 diabetes

Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*star for Targeted Cancer Therapies

Researcher carries out experiment in laboratory

Investigational treatment slowed lung function decline in IPF

Cartoon illustration of pink lungs

Boehringer Ingelheim Statement on Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

New global guidelines for progressive pulmonary fibrosis now available

Tackling Health Disparities and Inequities for Women with Heart Failure: New Program Encourages Black and Latina Women to Demand More From Their Care

Boehringer Ingelheim strengthens investment in R&D

Research and development laboratory

Phase III EMPA-KIDNEY trial will stop early

FDA Grants Breakthrough Therapy Designation for IPF

White graphic illustration of lungs

U.S. FDA grants priority review for spesolimab for the treatment of flares in patients with generalized pustular psoriasis (GPP), a rare, life-threatening skin disease

Yankees Legend Bernie Williams Teams Up With Multi-Platinum Recording Artist and Actress Jordin Sparks to Unveil New Song Featuring Lyrics From The Breathless® Ballad Challenge Winner

newspapers stacked on top of news sign

Boehringer Ingelheim’s Carine Boustany Appointed to BIO Board

US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction

Weill Cornell Medicine and NewYork-Presbyterian Hospital join Boehringer Ingelheim to study the incidence of progressive Interstitial Lung Disease in COVID-19 patients

Media Contacts

Head, U.S. Communications Human Pharma

900 Ridgebury Rd.
P.O. Box 368
Ridgefield, CT 06877

michele.baer@boehringer-ingelheim.com

Head, U.S. Communications
Animal Health

Phone +1 (913) 620-0026

rene.ward@boehringer-ingelheim.com

U.S. Communications

Phone +1 (203) 791-6487

belinda.martin@boehringer-ingelheim.com

Boehringer Ingelheim Animal Health USA Inc.
U.S. Communications

Phone +1 (516) 527-5456

christine.jones@boehringer-ingelheim.com